Adjuvant chemotherapy after neoadjuvant chemoradiation and surgery: A quest to improve survival for stage II and III rectal cancer

Max Vergo, Halla Nimeiri, Al B. Benson

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Combined multimodality treatments, including radiation, chemotherapy, and total mesorectal excision have been studied extensively over the past few decades, with efforts toward improving rates of locoregional recurrence and disease-free and overall survival in rectal cancer. Predictive and prognostic markers to adjuvant systemic chemotherapy have been identified, with the goal of tailoring therapy and continuing improvement in survival. In our article, we discuss these factors, including tumor downstaging, pathologic node status, gene expression, and future directions in therapy of rectal cancer.

Original languageEnglish (US)
Pages (from-to)151-157
Number of pages7
JournalCurrent Colorectal Cancer Reports
Volume5
Issue number3
DOIs
StatePublished - Jul 1 2009

ASJC Scopus subject areas

  • Hepatology
  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Adjuvant chemotherapy after neoadjuvant chemoradiation and surgery: A quest to improve survival for stage II and III rectal cancer'. Together they form a unique fingerprint.

Cite this